Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00822094
Recruitment Status : Completed
First Posted : January 14, 2009
Results First Posted : September 29, 2017
Last Update Posted : November 24, 2017
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Jazz Pharmaceuticals

Brief Summary:

The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens.

The study compares the investigational product CPX-351 vs the standard intensive salvage treatment for first relapse AML patients.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: CPX-351 Drug: Intensive Salvage Therapy Phase 2

Detailed Description:

This study is a randomized, open-label, parallel-arm, fixed-dose, standard therapy controlled Phase IIB trial. Study enrollment duration is expected to be approximately 12-18 months. On entry, patients are randomized to receive either CPX-351 or intensive first salvage treatment.

Patients are stratified to balance the likelihood of obtaining a CR and the duration of CR between the two arms.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 126 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration
Study Start Date : February 2009
Actual Primary Completion Date : December 2011
Actual Study Completion Date : January 2012

Arm Intervention/treatment
Experimental: CPX-351 (Arm A)
First induction: 100 units/m2 on Days 1, 3, and 5 by 90-minute IV infusion Second induction: 100 units/m2 on Days 1 and 3 by 90-minute IV infusion Consolidation(s): 100 units/m2 on Days 1 and 3 by 90-minute IV infusion
Drug: CPX-351
Active Comparator: Salvage Therapy (Arm B)
First induction: Investigator's choice salvage therapy administered according to local practice Second induction: Investigator's choice salvage therapy administered according to local practice Consolidation(s): Investigator's choice consolidation therapy administered according to local practice
Drug: Intensive Salvage Therapy

Primary Outcome Measures :
  1. Proportion of Subjects Surviving at 1 Year [ Time Frame: Up to 1 year from randomization ]
    The proportion of subjects surviving at 1 year was evaluated separately for each arm by the number of subjects alive at 1 year divided by the total number of subjects.

Secondary Outcome Measures :
  1. Complete Remission Rate [ Time Frame: Following 1st induction, following 2nd induction if applicable ]
  2. Event Free Survival [ Time Frame: Up to 1 year from randomization ]
    Progression EFS median

  3. Remission Duration [ Time Frame: Following achievement of CR and up to 1 year from randomization ]
    Remission duration was measured from the time the criteria for CR were first met until the first date that disease relapse was objectively documented or until subject death.

  4. Rate of Aplasia [ Time Frame: Up to 1 year from randomization ]
    Patients with Aplasia During Study

  5. Rate of Stem Cell Transplant [ Time Frame: Up to 1 year from randomization ]
    Number of patients transferred for stem cell transplant

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to understand and voluntarily sign an informed consent form
  • Age ≥18 and ≤65 years at the time of relapse
  • Pathological confirmation of relapsed AML after initial CR of >1 month duration
  • Eastern Cooperative Oncology Group (ECOG) performance status 0- 2
  • Able to adhere to the study visit schedule and other protocol requirements
  • Laboratory values fulfilling the following:

    • Serum creatinine < 2.0 mg/dL
    • Serum total bilirubin < 2.0 mg/dL
    • Serum alanine aminotransferase or aspartate aminotransferase <3xULN Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss.
  • Cardiac ejection fraction > 50% by echocardiography or MUGA scan
  • All men and women must agree to practice effective contraception during the study period and for 3 months afterward if not otherwise documented to be infertile.

Exclusion Criteria:

  • Patients with active second malignancies are excluded. Patients with second malignancies in remission may be eligible if there is no clinical evidence of active disease, documented by imaging, with tumor marker studies, etc., at screening. Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy, are eligible. In all cases, the second malignancy and its non-chemotherapy treatment must not interfere with the investigators ability to assess the safety or efficacy of the study treatment
  • Patients with acute promyelocytic leukemia [t(15;17)]
  • Total lifetime anthracycline exposure exceeding the equivalent of 368 mg/m2 of daunorubicin (or equivalent) prior to start of study therapy
  • Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent obtaining informed consent
  • Administration of any antineoplastic therapy within 4 weeks of therapy; intended to treat first relapse. In the event of rapidly proliferative disease use of hydroxyurea is permitted until 24 hours before the start of study treatment
  • Clinical evidence of active CNS leukemia
  • Patients with history of and/or current evidence of myocardial impairment (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in New York Heart Association Class III or IV staging
  • Active and uncontrolled infection. Patients with a bacterial infection receiving treatment with antibiotics may be entered into the study if they are afebrile and hemodynamically stable for >72 hrs.
  • Current evidence of invasive fungal infection (blood or tissue culture); active hepatitis C infection or known HIV infection
  • Hypersensitivity to cytarabine, daunorubicin or liposomal products
  • History of Wilson's disease or other copper-related disorder
  • Patients with a history of severe toxicity related to receiving conventional dose cytarabine in first line treatment (approximately 100mg/m2/d for <7 days) are excluded. Patients who experienced unacceptable toxicities while receiving high dose cytarabine (approximately 3000mg/m2 for 6 doses) will not be treated again with the same regimen, but could be randomized to treatment with conventional dose cytarabine regimens where the risk of major toxicity is less.
  • Woman who are pregnant or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00822094

  Show 42 Study Locations
Sponsors and Collaborators
Jazz Pharmaceuticals
The Leukemia and Lymphoma Society
Principal Investigator: Jonathan Kolitz, MD North Shore University Hospital

Additional Information:
Responsible Party: Jazz Pharmaceuticals Identifier: NCT00822094     History of Changes
Other Study ID Numbers: CLTR0308-205
First Posted: January 14, 2009    Key Record Dates
Results First Posted: September 29, 2017
Last Update Posted: November 24, 2017
Last Verified: October 2017

Keywords provided by Jazz Pharmaceuticals:
Acute Myelogenous leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Acute myelocytic leukemia

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Disease Attributes
Pathologic Processes